K. Behringer
Research Subjects
K. Behringer has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Volker Diehl
First Department of Internal Medicine, University of Cologne, Cologne, Germany
2 shared publications A Engert
German Hodgkin Study Group, Köln, Deutschland
1 shared publicationA Mayer
RWTH Aachen, Institut für Psychologie, Philosophische Fakultät, Köln, Deutschland
1 shared publicationA. Engert
1 shared publicationA. Josting
1 shared publicationC Bürkle
German Hodgkin Study Group, Köln, Deutschland
1 shared publication
Latest Publications
- 6 August 2018
- Published by Georg Thieme Verlag KG in PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
- Vol. 68 (08) , e8
Verlauf und Einflussfaktoren von Tumor-assoziierter Fatigue bei Hodgkin-Lymphom: eine longitudinale Studie der deutschen Hodgkin-Studiengruppe
Einleitung: Aktuelle Kombinationstherapien des Hodgkin-Lymphoms (HL) erreichen hohe Heilungsraten und viele Patienten mit HL sind jünger als 40 Jahre. Persistierende tumorassoziierte Fatigue führt in diesem jungen Kollektiv neben der hohen individuellen Belastung oft zu einer dauerhaften Beeinträchtigung des Berufslebens. Wir beschreiben hier Fatigue-Daten, die aus drei großen randomisierten Studien der GHSG stammen und sich über den Zeitraum von der Diagnose bis fünf Jahre nach Therapie erstrecken. Material & Methoden: Eingeschlossen wurden Patienten mit Erstmanifestation eines HL in frühen (HD13), mittleren (HD14) und fortgeschrittenen (HD15) Stadien. Die Erfassung der tumorassoziierten Fatigue erfolgte mit der von 0 bis 100 reichenden Fatigue-Skala (FA) des EORTC-QLQ-C30. Therapieeffekte bestimmten wir mit multipler linearer Regression und unterschiedliche FA-Trajektorien innerhalb der Studien mit Growth-Mixture-Modellen (GMM). Ergebnisse: Wir analysierten FA-Daten von insgesamt 4215 HL-Patienten in einem Alter von 18 – 60 Jahren bei Studieneinschluss. Patienten mit höherer Tumorbelastung berichteten bereits vor Therapie mehr Fatigue (mittlere FA in HD13 = 30,8, HD14 = 39,8 und HD15 = 49,0). Nach weiterem Anstieg der FA-Werte unter Therapie lagen bereits kurz danach deutlich niedrigere und in allen drei Studien ähnlich hohe FA-Werte von ≈25 – 30 vor. Es waren keinerlei Therapieeffekte auf die persistierende Fatigue nachweisbar, jedoch ein starker Einfluss der Ausgangswerte vor Therapie. Die GMM identifizierten 3 – 4 unterschiedliche FA-Trajektorien in jeder Studie, die nach Therapie teils stabile teils reduzierte Fatigue-Werte zeigten, jedoch nie therapieinduzierte FA-Anstiege. Diskussion & Schlussfolgerung: Unsere Studie belegt ein hohes, klinisch relevantes Maß an Fatigue vor und nach Therapie des HL. Dabei ist die persistierende Fatigue weitgehend unabhängig von initialem Stadium und erfolgter Therapie. Unsere Ergebnisse stützen Behandlungskonzepte der Fatigue, die an aufrechterhaltenden psychosozialen Faktoren ansetzen. Literatur: [1] Kreissl, S., Müller, H., Görgen, H. et. al. (2016). Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncology, 17(10):1453 – 1462.
- 6 August 2018
- Published by Georg Thieme Verlag KG in PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
- Vol. 68 (08) , e8
Verlauf und Einflussfaktoren von Tumor-assoziierter Fatigue bei Hodgkin-Lymphom: eine longitudinale Studie der deutschen Hodgkin-Studiengruppe
Einleitung: Aktuelle Kombinationstherapien des Hodgkin-Lymphoms (HL) erreichen hohe Heilungsraten und viele Patienten mit HL sind jünger als 40 Jahre. Persistierende tumorassoziierte Fatigue führt in diesem jungen Kollektiv neben der hohen individuellen Belastung oft zu einer dauerhaften Beeinträchtigung des Berufslebens. Wir beschreiben hier Fatigue-Daten, die aus drei großen randomisierten Studien der GHSG stammen und sich über den Zeitraum von der Diagnose bis fünf Jahre nach Therapie erstrecken. Material & Methoden: Eingeschlossen wurden Patienten mit Erstmanifestation eines HL in frühen (HD13), mittleren (HD14) und fortgeschrittenen (HD15) Stadien. Die Erfassung der tumorassoziierten Fatigue erfolgte mit der von 0 bis 100 reichenden Fatigue-Skala (FA) des EORTC-QLQ-C30. Therapieeffekte bestimmten wir mit multipler linearer Regression und unterschiedliche FA-Trajektorien innerhalb der Studien mit Growth-Mixture-Modellen (GMM). Ergebnisse: Wir analysierten FA-Daten von insgesamt 4215 HL-Patienten in einem Alter von 18 – 60 Jahren bei Studieneinschluss. Patienten mit höherer Tumorbelastung berichteten bereits vor Therapie mehr Fatigue (mittlere FA in HD13 = 30,8, HD14 = 39,8 und HD15 = 49,0). Nach weiterem Anstieg der FA-Werte unter Therapie lagen bereits kurz danach deutlich niedrigere und in allen drei Studien ähnlich hohe FA-Werte von ≈25 – 30 vor. Es waren keinerlei Therapieeffekte auf die persistierende Fatigue nachweisbar, jedoch ein starker Einfluss der Ausgangswerte vor Therapie. Die GMM identifizierten 3 – 4 unterschiedliche FA-Trajektorien in jeder Studie, die nach Therapie teils stabile teils reduzierte Fatigue-Werte zeigten, jedoch nie therapieinduzierte FA-Anstiege. Diskussion & Schlussfolgerung: Unsere Studie belegt ein hohes, klinisch relevantes Maß an Fatigue vor und nach Therapie des HL. Dabei ist die persistierende Fatigue weitgehend unabhängig von initialem Stadium und erfolgter Therapie. Unsere Ergebnisse stützen Behandlungskonzepte der Fatigue, die an aufrechterhaltenden psychosozialen Faktoren ansetzen. Literatur: [1] Kreissl, S., Müller, H., Görgen, H. et. al. (2016). Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncology, 17(10):1453 – 1462.
- 1 January 2006
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (4) , 461-465
Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin's Lymphoma?
In 1992, the German Hodgkin Study Group (GHSG) developed the BEACOPP regimen for further improving the outcome of patients with advanced Hodgkin's lymphoma (HL). Since then, BEACOPP has been introduced in 3 different prospective randomized clinical trials of the GHSG to find an equilibrium between maximal efficacy and least toxicity with the BEACOPP principle for the treatment of advanced stage HL. In the HD9 trial of the GHSG, with 1,186 patients, after a median observation time of 7 years, the rates for FFTF are 85 percent and for overall survival 90 percent for dose-escalated BEACOPP, and for COPP/ABVD (C/ABVD comparable to ABVD) the rate for FFTF is 67 percent and for overall survival it is 79 percent. These superior BEACOPP results are obtained inspite of a higher rate of secondary AML/MDS in the escalated BEACOPP arm. The number of toxic deaths during treatment, however, was lower for escalated BEACOPP (1.6 percent) than for C/ABVD (1.8 percent). The majority of patients were treated in an outpatient setting, in a multicenter study with more than 400 centers, including 120 private doctors, located in Germany and 9 other European countries. To reduce acute and long-term toxicity, the GHSG started in the consecutive studies HD12 and HD15 for advanced stage HL to de-escalate BEACOPP by reducing the number of escalated BEACOPP cycles and by applying the baseline dose BEACOPP, a time dense regimen, called BEACOPP-14. The excellent results obtained with the BEACOPP principle challenge the seemingly global consensus that ABVD is the gold standard treatment strategy for advanced stage HL.
- 1 January 2006
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (4) , 461-465
Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin's Lymphoma?
In 1992, the German Hodgkin Study Group (GHSG) developed the BEACOPP regimen for further improving the outcome of patients with advanced Hodgkin's lymphoma (HL). Since then, BEACOPP has been introduced in 3 different prospective randomized clinical trials of the GHSG to find an equilibrium between maximal efficacy and least toxicity with the BEACOPP principle for the treatment of advanced stage HL. In the HD9 trial of the GHSG, with 1,186 patients, after a median observation time of 7 years, the rates for FFTF are 85 percent and for overall survival 90 percent for dose-escalated BEACOPP, and for COPP/ABVD (C/ABVD comparable to ABVD) the rate for FFTF is 67 percent and for overall survival it is 79 percent. These superior BEACOPP results are obtained inspite of a higher rate of secondary AML/MDS in the escalated BEACOPP arm. The number of toxic deaths during treatment, however, was lower for escalated BEACOPP (1.6 percent) than for C/ABVD (1.8 percent). The majority of patients were treated in an outpatient setting, in a multicenter study with more than 400 centers, including 120 private doctors, located in Germany and 9 other European countries. To reduce acute and long-term toxicity, the GHSG started in the consecutive studies HD12 and HD15 for advanced stage HL to de-escalate BEACOPP by reducing the number of escalated BEACOPP cycles and by applying the baseline dose BEACOPP, a time dense regimen, called BEACOPP-14. The excellent results obtained with the BEACOPP principle challenge the seemingly global consensus that ABVD is the gold standard treatment strategy for advanced stage HL.
- 1 January 2006
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (7) , 713-717
Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin's Lymphoma (HL)?
In 1992, the German Hodgkin Study Group (GHSG) developed the BEACOPP regimen for further improving the outcome of patients with advanced Hodgkin's lymphoma (HL). Since then, BEACOPP has been introduced in 3 different prospective randomized clinical trials of the GHSG to find an equilibrium between maximal efficacy and least toxicity with the BEACOPP principle for the treatment of advanced stage HL. In the HD9 trial of the GHSG, with 1,186 patients, after a median observation time (mot) of 7 years, the rates for freedom from treatment failure (FFTF) are 85 percent, and for overall survival (OS) 90 percent for dose-escalated BEACOPP, and for COPP/ABVD (C/ABVD comparable to ABVD) the rate for FFTF is 67 percent, and for OS it is 79 percent. These superior BEACOPP results are obtained inspite of a higher rate of secondary AML/MDS in the esc. BEACOPP arm. The number of toxic deaths during treatment, however, was lower for esc. BEACOPP (1.6 percent) than for C/ABVD (1.8 percent). The majority of patients were treated in outpatient setting, in a multicenter study with more than 400 centers, including 120 private doctors, in Germany and 9 other European countries. The reduce acute and longterm toxicity, the GHSG started in the consecutive studies HD12 and HD15 for advanced stage HL to de-escalate BEACOPP by reducing the number of escalated BEACOPP cycles and by applying the baseline-dose BEACOPP, a time-dense regimen, called BEACOPP-14. The excellent results obtained with the BEACOPP principle challenge the seemingly global consensus that ABVD is the gold standard treatment strategy for advanced stage HL.
- 1 January 2006
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (7) , 713-717
Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin's Lymphoma (HL)?
In 1992, the German Hodgkin Study Group (GHSG) developed the BEACOPP regimen for further improving the outcome of patients with advanced Hodgkin's lymphoma (HL). Since then, BEACOPP has been introduced in 3 different prospective randomized clinical trials of the GHSG to find an equilibrium between maximal efficacy and least toxicity with the BEACOPP principle for the treatment of advanced stage HL. In the HD9 trial of the GHSG, with 1,186 patients, after a median observation time (mot) of 7 years, the rates for freedom from treatment failure (FFTF) are 85 percent, and for overall survival (OS) 90 percent for dose-escalated BEACOPP, and for COPP/ABVD (C/ABVD comparable to ABVD) the rate for FFTF is 67 percent, and for OS it is 79 percent. These superior BEACOPP results are obtained inspite of a higher rate of secondary AML/MDS in the esc. BEACOPP arm. The number of toxic deaths during treatment, however, was lower for esc. BEACOPP (1.6 percent) than for C/ABVD (1.8 percent). The majority of patients were treated in outpatient setting, in a multicenter study with more than 400 centers, including 120 private doctors, in Germany and 9 other European countries. The reduce acute and longterm toxicity, the GHSG started in the consecutive studies HD12 and HD15 for advanced stage HL to de-escalate BEACOPP by reducing the number of escalated BEACOPP cycles and by applying the baseline-dose BEACOPP, a time-dense regimen, called BEACOPP-14. The excellent results obtained with the BEACOPP principle challenge the seemingly global consensus that ABVD is the gold standard treatment strategy for advanced stage HL.
- Open Access
- 1 July 2004
- Published by Elsevier in Annals of Oncology
- Vol. 15 (7) , 1079-1085
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group
Background: Long-term survivors of successfully treated Hodgkin's disease (HD) are at risk for late complications. Among these, secondary solid tumors are most serious because they are often fatal. The aim of this retrospective analysis was to assess the incidence, relative risk and risk factors of secondary solid tumors in HD patients registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). Patients and methods: From 1983 to 1998, the GHSG conducted three generations of clinical trials for early, intermediate and advanced stage HD (HD1–HD9) involving a total of 5367 patients. Data on incidence, risk factors and relative risk were updated in March 2003. Results: A total of 127 patients with secondary solid tumors were identified. Among these, lung cancer (23.6%), colorectal cancer (20.5%) and breast cancer (10.2%) were the most frequent. After a median follow-up of 72 months the cumulative risk of developing a solid tumor was 2%, with an overall relative risk (RR) of 2.4 (lung cancer, 3.8; colorectal cancer, 3.2; breast cancer, 1.9). For most patients (n=67; 52.8%) developing a secondary solid tumor, treatment modality consisted of chemotherapy combined with radiotherapy in extended field technique (RR = 3.3). Conclusions: With a median follow-up of 72 months, there were 127 patients developing solid tumors out of a total of 5367 HD patients treated in the GHSG studies HD1–HD9. The cumulative risk of 2% is expected to increase over time due to the rather short median observation time and slow progression of solid malignancies.
- 1 July 2004
- Published by Elsevier in Annals of Oncology
- Vol. 15 (7) , 1079-1085
Open AccessSolid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group
Background: Long-term survivors of successfully treated Hodgkin's disease (HD) are at risk for late complications. Among these, secondary solid tumors are most serious because they are often fatal. The aim of this retrospective analysis was to assess the incidence, relative risk and risk factors of secondary solid tumors in HD patients registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). Patients and methods: From 1983 to 1998, the GHSG conducted three generations of clinical trials for early, intermediate and advanced stage HD (HD1–HD9) involving a total of 5367 patients. Data on incidence, risk factors and relative risk were updated in March 2003. Results: A total of 127 patients with secondary solid tumors were identified. Among these, lung cancer (23.6%), colorectal cancer (20.5%) and breast cancer (10.2%) were the most frequent. After a median follow-up of 72 months the cumulative risk of developing a solid tumor was 2%, with an overall relative risk (RR) of 2.4 (lung cancer, 3.8; colorectal cancer, 3.2; breast cancer, 1.9). For most patients (n=67; 52.8%) developing a secondary solid tumor, treatment modality consisted of chemotherapy combined with radiotherapy in extended field technique (RR = 3.3). Conclusions: With a median follow-up of 72 months, there were 127 patients developing solid tumors out of a total of 5367 HD patients treated in the GHSG studies HD1–HD9. The cumulative risk of 2% is expected to increase over time due to the rather short median observation time and slow progression of solid malignancies.